H
Hirotsugu Uemura
Researcher at Kindai University
Publications - 373
Citations - 9734
Hirotsugu Uemura is an academic researcher from Kindai University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 35, co-authored 318 publications receiving 7829 citations. Previous affiliations of Hirotsugu Uemura include Aichi Medical University & University of Southern California.
Papers
More filters
Journal ArticleDOI
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini,Bernard Escudier,Piotr Tomczak,Andrey Kaprin,Cezary Szczylik,Thomas E. Hutson,M. Dror Michaelson,Vera Gorbunova,Martin Gore,Igor G. Rusakov,Sylvie Negrier,Yen Chuan Ou,Daniel Castellano,Ho Yeong Lim,Hirotsugu Uemura,Jamal Tarazi,David Cella,Connie Chen,Brad Rosbrook,Sinil Kim,Robert J. Motzer +20 more
TL;DR: Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib.
Journal ArticleDOI
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,David Cella,James Reeves,Robert E. Hawkins,Jun Guo,Paul Nathan,Michael Staehler,Paul de Souza,Jaime R. Merchan,Ekaterini Boleti,Kate Fife,Jie Jin,Robert Jones,Hirotsugu Uemura,Ugo De Giorgi,Ulrika Harmenberg,Jinwan Wang,Cora N. Sternberg,Keith C. Deen,Lauren McCann,Michelle D. Hackshaw,Rocco Crescenzo,Lini Pandite,Toni K. Choueiri +24 more
TL;DR: Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazoSmithKline Pharmaceuticals.
Journal ArticleDOI
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N. Chi,Neeraj Agarwal,Anders Bjartell,Byung Ha Chung,Andrea J. Pereira de Santana Gomes,Robert Given,Álvaro Juárez Soto,Axel S. Merseburger,Mustafa Ozguroglu,Hirotsugu Uemura,Dingwei Ye,Kris Deprince,V. Naini,Jinhui Li,Shinta Cheng,Margaret K. Yu,Ke Zhang,Julie S. Larsen,Sharon Anne McCarthy,Simon Chowdhury +19 more
TL;DR: Overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups.
Journal ArticleDOI
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri,James Larkin,Mototsugu Oya,Fiona C Thistlethwaite,Fiona C Thistlethwaite,Marcella Martignoni,Paul Nathan,Thomas Powles,David F. McDermott,Paul B. Robbins,David D. Chism,Daniel Cho,Michael B. Atkins,Michael S. Gordon,Sumati Gupta,Hirotsugu Uemura,Yoshihiko Tomita,Anna Compagnoni,Camilla Fowst,Alessandra di Pietro,Brian I. Rini +20 more
TL;DR: The safety profile of the combination avelumab plus axitinib in treatment-naive patients with advanced renal-cell carcinoma seemed to be manageable and consistent with that of each drug alone, and the preliminary data on antitumour activity are encouraging.
Journal ArticleDOI
Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
Dorothy A. White,Philippe Camus,Masahiro Endo,Bernard Escudier,Emiliano Calvo,Hideyuki Akaza,Hirotsugu Uemura,Euloge Kpamegan,Andrea Kay,Matthew Robson,Alain Ravaud,Robert J. Motzer +11 more
TL;DR: Early recognition, prompt intervention, and a conservative approach are important in managing the risk associated with noninfectious pneumonitis in association with everolimus.